知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.017 seconds)

    Peptides and related molecules that bind to TALL-1
    4.
    发明授权
    Peptides and related molecules that bind to TALL-1 有权
    结合TALL-1的肽和相关分子

    公开(公告)号：US09139645B2

    公开(公告)日：2015-09-22

    申请号：US13938141

    申请日：2013-07-09

    Applicant: AMGEN INC.

    Inventor： Hosung Min ,  Hailing Hsu ,  Fei Xiong

    IPC: C07K7/08 ,  C07K14/00 ,  C07K16/24 ,  C07K1/04 ,  C07K14/47 ,  C07K14/715 ,  C12N15/10 ,  C40B40/02 ,  A61K38/00

    CPC classification number: C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  C07K1/047 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/7151 ,  C07K16/241 ,  C07K2319/30 ,  C07K2319/74 ,  C12N15/1037 ,  C40B40/02

    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a—V1—(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

    Abstract translation: 本发明涉及调节TALL-1活性的治疗剂。 根据本发明，TALL-1的调节剂可以包含氨基酸序列Dz2Lz4，其中z2是氨基酸残基，z4是苏氨酰基或异亮氨酰基。 示例性分子包括下式的一个序列（SEQ。ID NO：100）a1a2a3CDa6La8a9a10Ca12a13a14，（SEQ ID NO：104）b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18（SEQ ID。NO：105）c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18（SEQ ID。NO：106）d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18（ SEQ ID NO：107）e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18（SEQ ID NO：109）f1f2f3Kf5Df7Lf9f10Qf12f13f14其中取代基如说明书中所定义。 本发明还包括式（X1）a-V1-（X2）b的物质的组合物，其中V1是共价连接到一种或多种上述TALL-1调节组合物的载体。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域，优选的Fc结构域是IgG Fc结构域。

    Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
    6.
    发明授权
    Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof 有权

    公开(公告)号：US11104745B2

    公开(公告)日：2021-08-31

    申请号：US16062096

    申请日：2016-12-14

    Applicant: AMGEN INC.

    Inventor： Hailing Hsu ,  Gunasekaran Kannan ,  Kenneth W. Walker ,  Michelle Hortter ,  Edward J. Belouski

    IPC: C07K16/46 ,  C07K16/24 ,  A61K39/395 ,  C07K16/28 ,  C12N15/10

    Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.

Patent Agency Ranking